Meeting
2017 ASCO Annual Meeting
The use of 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET in the evaluation of breast cancer heterogeneity.
Authors
Lanell M Peterson
University of Washington Seattle Cancer Care Alliance, Seattle, WA
Lanell M Peterson , Brenda F Kurland , Alena Novakova , Jean H Lee , Jennifer M. Specht , Mark Muzi , Perrin Romine , Vicky Wu , David A. Mankoff , Paul Kinahan , Hannah M. Linden
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11572)
DOI
10.1200/JCO.2017.35.15_suppl.11572
Abstract #
11572
Poster Bd #
272
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
18F-Fluoroestradiol (FES) and 18F-Fluorodeoxyglucose (FDG) PET imaging in lobular breast cancer.
First Author: Poorni Manohar
Poster
2022 ASCO Annual Meeting
Matched FES and FDG PET imaging in patients with hormone receptor-positive, HER2+ advanced breast cancer.
First Author: Natasha Hunter
First Author: Jason Brown
Poster
2016 ASCO Annual Meeting
A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.
First Author: Elisabeth De Vries